Inflammatory Disease :: Array BioPharma’s MEK Inhibitor, ARRY-438162, meets initial clinical objectives

Array BioPharma Inc. (Nasdaq: ARRY) announced that its first-in-class MEK inhibitor for the treatment of inflammatory diseases, ARRY-438162, has met its primary objectives in a single ascending dose clinical study involving 20 healthy volunteers. These results were presented by Array?s President and Chief Scientific Officer, Kevin Koch, Ph.D., at the 14th International Inflammation Research Association Conference in Cambridge, Maryland.

Diet :: Apples and apple juice – quercetin antioxidant good for neurological health

For those who think that picking and eating apples this time of year is just for fun and for the great taste of America’s favorite fruit, you may want to think again. Apples and apple juice may be among the best foods that anyone could add to their diet, finds a collection of recent research studies, the latest of which was presented yesterday at the Society of Neuroscience annual conference in Atlanta. Researchers G. Bureau and M. Martinoli from the University of Quebec a Trois-Rivieres, found that quercetin (one of the antioxidants found abundantly in apples) was one of two compounds that helped to reduce cellular death that is caused by oxidation and inflammation of neurons.

Hearing Loss :: Listening to loud music with earphones harmful

Listening to loud music with earphones on a digital music player for more than 90 minutes a day can damage your hearing, according to a new U.S. study. The study of 100 doctoral students concluded that people who listened to music at 80 percent of volume capacity, at which point the sound is considered loud, should stick to under 90 minutes a day.

Influenza :: Novartis cell culture-derived influenza vaccine well tolerated and efficacious

Novartis (NYSE: NVS) announced today results of pivotal Phase III clinical trial data for its innovative cell culture-derived influenza vaccine demonstrating that it is highly capable of producing an immune response (“immunogenic”), one at least as strong as the traditional egg-derived influenza vaccine Aggripal? for each of the three influenza strains studied.

Diabetes :: NovoMix insulin – effective & safe for patients with type 2 diabetes

Data presented at the European Association for the Study of Diabetes (EASD) 42nd Conference in Copenhagen showed NovoMix? 30 (biphasic insulin aspart) to have comparable efficacy to basal-bolus combination therapy, with a similar safety profile in patients previously treated with oral antidiabetic therapy. These findings follow on from the European Commission?s recent decision to approve NovoMix? 30 as the first premixed insulin suitable for once-daily initiation and subsequent intensification of treatment, if needed. The data also confirm the position of NovoMix? 30 as an appropriate treatment choice for patients who prefer a convenient, effective once or twice-daily insulin therapy.

Asthma :: Asthma and soot from diesel trucks in bronx linked

Soot particles spewing from the exhaust of diesel trucks constitute a major contributor to the alarmingly high rates of asthma symptoms among school-aged children in the South Bronx, according to the results of a five-year study by researchers at New York University’s School of Medicine and Robert F. Wagner Graduate School of Public Service.

Pregnancy :: Woman gave birth to her own grandchild in Japan

A woman in her 50s gave birth last year to a baby she had carried for her daughter, who is unable to bear children, the head of a maternity clinic in Nagano Prefecture announced Sunday. The revelation could stir further debate about births by surrogate mothers, which are opposed by both the health ministry and the nation’s obstetrician association.

HIV :: Virco introduces an improved rapid methodology to establish new hiv-1 resistance profiles

Responding to the need to make timely evaluations and decisions when treating treatment experienced HIV patients, Virco (http://www.vircolab.com), a leader in drug resistance testing recently introduced an improved virco(R)TYPE HIV-1 test that rapidly determines the complex phenotypic resistance profiles for darunavir, tipranavir and other antiretroviral (ARV) drugs. Utilizing clinical trial data that was used to support the approval of darunavir and tipranavir, virco(R)TYPE HIV-1 reports now include Clinical Cut-Offs (CCOs) for these recently introduced agents(1). Virco(R)TYPE HIV-1 analyzes patient HIV-1 resistant genotypes using Virco’s large database to quickly and accurately predict phenotypic resistance. This timely determination of phenotypic resistance assists physicians in choosing a drug treatment plan that has the least amount of drug resistance.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack